NASDAQ · Financial Statements
Definium Therapeutics, Inc. (DFTX) Financial Statements
$36.90
NASDAQ: DFTX
Market Cap $4.90B
Overview Financials Dividend Definium Therapeutics, Inc. most recently reported annual revenue of $0, net profit of $-184.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $0 $0 $0 $0 $0 Operating Profit $-94.0M $-66.0M $-94.0M $-104.0M $-166.0M Net Profit $-93.0M $-57.0M $-96.0M $-109.0M $-184.0M EPS $-3.40 $-1.53 $-2.44 $-0.15 $-2.06 Op Margin — — — — —
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $164.0M $170.0M $125.0M $302.0M $440.0M Total Liabilities $12.0M $19.0M $46.0M $61.0M $108.0M Cash $134.0M $142.0M $100.0M $274.0M $258.0M Borrowings $0 $0 $14.0M $22.0M $0
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $-46.0M $-50.0M $-64.0M $-79.0M $-132.0M Investing Cash Flow $0 $0 $0 $0 $-152.0M Financing Cash Flow $17.0M $17.0M $0 $-8.0M $-13.0M Net Cash Flow $53.0M $9.0M $-42.0M $174.0M $-16.0M Free Cash Flow $-46.0M $-50.0M $-64.0M $-79.0M $-132.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.15 EV / EBITDA -12.79 FCF Yield -3.36% Quick Ratio 6.95 Interest Coverage -16.92 Return 1Y 326.07% Return 3Y 846.47% Return 5Y -9.01%
Screens featuring this stock